Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXL01 + nivolumab + FOLFOX vs nivolumab + FOLFOX in first-line PD-L1 CPS ≥5 metastatic gastric cancer (BIG)
2023-506753-38-00Phase 2Authorised
- Sponsor
- GERCOR
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric adenocarcinoma, Esophago-Gastric Adenocarcinoma and esophageal adenocarcinoma (EAC) comparing EXL01 + nivolumab + FOLFOX with nivolumab + FOLFOX (2 arms). Primary endpoint: Primary ORR at 4 months. Planned start Jan 2024; status: authorised.
02
Drugs
03
Conditions
gastric adenocarcinomaEsophago-Gastric Adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2023-506753-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506753-38-00.